SANOFI SpA
Bisolvon Linctus Mucolytic Syrup for Fatty Cough 250 ml 4 mg/5 ml
Bisolvon Linctus Mucolytic Syrup for Fatty Cough 250 ml 4 mg/5 ml

Couldn't load pickup availability
PRODUCT NET WEIGHT
PRODUCT NET WEIGHT
250ml
EAN
EAN
021004041
MINSAN
MINSAN
021004041
Bisolvon Linctus is a Bromexine-based syrup with mucolytic action suitable for adults, adolescents and children. Useful in case of acute and chronic respiratory diseases, with cough and production of phlegm .
Bisolvon Linctus concentrates at the level of bronchial and pulmonary tissue, where phlegm is present. Here it acts with its triple effect:
-
It thins mucus deposits in the respiratory tract.
-
It helps to expectorate and eliminate phlegm.
-
Calms coughs.
Bisolvon Linctus syrup contains neither sucrose nor fructose and can be administered to diabetics.
ACTIVE INGREDIENTS
Active ingredients contained in Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg/5 ml - What is the active ingredient of Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg/5 ml?
5 ml of syrup contain; active ingredient: bromexine hydrochloride 4 mg (equivalent to bromexine 3.65 mg). Excipient with known effect: maltitol. For the full list of excipients, see section 6.1.
EXCIPIENTS
Composition of Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg/5 ml - What does Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg/5 ml contain?
Benzoic acid, liquid maltitol, sucralose, chocolate flavor, cherry flavor, levomenthol, purified water.
DIRECTIONS
Therapeutic indications Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg/5 ml - Why is Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg/5 ml used? What is it used for?
Bisolvon is indicated in the treatment of secretion disorders in acute and chronic respiratory diseases.
CONTRAINDICATIONS SIDE EFFECTS
Contraindications Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg/5 ml - When should Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg/5 ml not be used?
Hypersensitivity to the active substance or to any of the excipients. The drug is contraindicated in children under 2 years of age. In case of hereditary conditions that may be incompatible with one of the excipients (see 4.4). There are no absolute contraindications, but in patients with gastroduodenal ulcer, its use is recommended after consulting the doctor. Contraindicated during breastfeeding (see section 4.6).
DOSAGE
Quantity and method of taking Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg/5 ml - How do you take Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg/5 ml?
The following dosages are recommended unless otherwise prescribed by your doctor. Adults: 5 - 10 ml 3 times a day. In adults, at the beginning of treatment, it may be necessary to increase the total daily dose up to 48 mg divided into three times. Children over 2 years of age: 2.5 - 5 ml 3 times a day. It is recommended to take the medicine after meals. The syrup can be administered to diabetics and children over 2 years of age, it does not contain fructose or sucrose. Do not exceed the recommended doses. To measure the appropriate dose, use the measuring cup included in the package (with marks at 1.25 ml equal to 1 mg of bromexine hydrochloride, 2.5 equal to 2 mg of bromexine hydrochloride and 5 ml equal to 4 mg of bromexine hydrochloride).
CONSERVATION
Storage Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg/5 ml - How is Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg/5 ml stored?
This medicinal product does not require any special storage conditions.
WARNINGS
Warnings Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg/5 ml - About Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg/5 ml it is important to know that:
Treatment with Bisolvon leads to increased bronchial secretion (this promotes expectoration). Do not use for prolonged treatment. In the treatment of acute respiratory conditions, consult your doctor if symptoms do not improve or worsen during therapy. Cases of serious skin reactions such as erythema multiforme, Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (AGEP) have been reported in association with the administration of bromhexine hydrochloride. If symptoms or signs of progressive skin rash (sometimes associated with blisters or mucosal lesions) are present, treatment with bromhexine hydrochloride should be stopped immediately and a doctor should be consulted. Most of these reactions could be explained by the severity of underlying diseases or other drugs taken at the same time. In addition, in the early stages of Stevens-Johnson syndrome or toxic epidermal necrolysis (TEN), patients may initially experience non-specific flu-like symptoms, such as fever, chills, rhinitis, cough and sore throat. Because of these misleading symptoms, symptomatic treatment with cough and cold therapy may be initiated. Mucolytics may induce bronchial obstruction in children under 2 years of age. In fact, the ability to drain bronchial mucus is limited in this age group, due to the physiological characteristics of the airways. They should therefore not be used in children under 2 years of age (see section 4.3). The medicinal product contains liquid maltitol: the maximum recommended daily dose of Bisolvon 4 mg/5 ml contains 15 g of maltitol (30 g in case of increased daily dose in adults at the start of treatment), patients with rare problems of fructose intolerance should not take this medicinal product. This medicine may have a mild laxative effect.
INTERACTIONS
Interactions Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg/5 ml - Which medicines or foods can modify the effect of Bisolvon Linctus Mucolytic Syrup Chesty Cough 250 ml 4 mg/5 ml?'
No clinically relevant interactions with other medicinal products have been reported.
SIDE EFFECTS
Like all medicines, Bisolvon Linctus Mucolytic Syrup for Chesty Cough 250 ml 4 mg/5 ml can cause side effects - What are the side effects of Bisolvon Linctus Mucolytic Syrup for Chesty Cough 250 ml 4 mg/5 ml?
Frequencies are defined using the following convention: very common: >= 1/10; common: >= 1/100, < 1/10; uncommon: >= 1/1,000, < 1/100; rare: >= 1/10,000, < 1/1,000; very rare: < 1/10,000; not known: frequency cannot be estimated from the available data. Immune system disorders: Rare: hypersensitivity reactions; not known: anaphylactic reactions, including anaphylactic shock, angioedema and pruritus. Respiratory, thoracic and mediastinal disorders: Not known: bronchospasm. Gastrointestinal disorders: Uncommon: nausea, vomiting, diarrhoea and upper abdominal pain. Skin and subcutaneous tissue disorders: Rare: rash, urticaria; not known: serious cutaneous adverse reactions (including erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis, and acute generalized exanthematous pustulosis). Reporting of suspected adverse reactions. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at http://www.agenziafarmaco.gov.it/it/responsabili.
PREGNANCY AND BREASTFEEDING
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Bisolvon Linctus Mucolytic Syrup for Chesty Cough 250 ml 4 mg/5 ml
No studies have been conducted to investigate the effects on human fertility. Based on preclinical experience there is no indication of possible effects on fertility following the use of bromhexine. There are limited data on the use of bromhexine in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of Bisolvon during pregnancy. It is not known whether bromhexine and its metabolites pass into human milk. Available pharmacodynamic and toxicological data in animals have shown excretion of bromhexine and its metabolites in breast milk. A risk to breast-fed children cannot be excluded. Bisolvon should not be used during breast-feeding.
